Greg Jennings LLC Acquires 3,279 Shares of Quest Diagnostics Incorporated $DGX

Posted by Brian Himes on Oct 19th, 2026

Greg Jennings LLC purchased a new stake in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,279 shares of the medical research company’s stock, valued at approximately $764,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Quest Diagnostics in the second quarter valued at approximately $1,965,923,000. EdgePoint Investment Group Inc. boosted its position in shares of Quest Diagnostics by 35.1% in the first quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock valued at $439,753,000 after acquiring an additional 582,797 shares during the period. Bank of America Corp DE bought a new stake in shares of Quest Diagnostics in the second quarter valued at approximately $410,151,000. Dimensional Fund Advisors LP increased its holdings in Quest Diagnostics by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,949,535 shares of the medical research company’s stock valued at $382,085,000 after buying an additional 17,987 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Quest Diagnostics by 11.3% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 942,407 shares of the medical research company’s stock worth $199,743,000 after buying an additional 95,804 shares during the last quarter. 88.06% of the stock is owned by institutional investors.

Quest Diagnostics Stock Down 0.0%

Shares of NYSE:DGX traded down $0.08 during trading on Monday, reaching $234.92. 864,589 shares of the stock traded hands, compared to its average volume of 977,358. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59. The stock has a market cap of $25.93 billion, a P/E ratio of 24.94, a price-to-earnings-growth ratio of 2.13 and a beta of 0.54. The stock has a 50-day moving average of $237.40 and a two-hundred day moving average of $215.48. Quest Diagnostics Incorporated has a 52-week low of $171.18 and a 52-week high of $248.84.

Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same period last year, the firm posted $2.62 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, sell-side analysts expect that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th will be paid a $0.86 dividend. This represents a $3.44 annualized dividend and a yield of 1.5%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio is presently 36.52%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Mizuho boosted their price target on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Barclays upped their price target on shares of Quest Diagnostics from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Wall Street Zen upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. Truist Financial increased their price target on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock a “hold” rating in a report on Monday, September 21st. Finally, JPMorgan Chase & Co. boosted their target price on Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $238.23.

View Our Latest Stock Report on DGX

Insider Activity

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the sale, the chief executive officer directly owned 122,423 shares in the company, valued at $29,714,510.56. This represents a 7.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total transaction of $376,288.00. Following the completion of the sale, the senior vice president owned 10,335 shares of the company’s stock, valued at $2,430,585.30. This trade represents a 13.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 34,277 shares of company stock worth $8,316,493 over the last 90 days. Corporate insiders own 0.88% of the company’s stock.

Quest Diagnostics Company Profile

(Free Report)

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.